Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
2d
Zacks.com on MSNRHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity DrugRoche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...
Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...
Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results